Working with the NHS as a Strategic National Account Manager for Boehringer Ingelheim can be a joy, a frustration and sometimes a lonely experience. It’s great to be able to celebrate projects that improve patients’ lives, but there are other times when people make a negative judgement about working with a pharmaceutical company on preconception and that’s really frustrating. The lonely times come as a result of working alone to drive projects through a myriad of internal and external processes. It’s that principle that drove me to try something different.
Tuesday 20th October 2015 saw the Communications Team launch BI’s health policy briefing document in the Strangers Dining Room at the House of Commons. The policy document has been developed by the team to outline specific asks of the recently elected Government on issues such as NICE, the Pharmaceutical Price Regulation Scheme (PPRS), Specialised Commissioning and in the therapy areas where we major.
Coinciding with the State Visit to Parliament by the President of China, there was a moment when it looked like people weren’t going to be able to gain access to the building, but we remained calm and welcomed over 50 guests to our reception. These were made up of a wide range of our stakeholders, including MPs from all sides of the House, Lords with an interest in Health, staff from the Department of Health and NHS England – including the Chair of NICE and the National Clinical Director for Diabetes – and a range of clinical stakeholders who had come to hear what we had to say, along with representatives from patient organisations with whom we have been working closely over the last few years. Continue reading Health Policy Briefing Document launches at Reception in Parliament→
The great and good of the National Institute for Health and Care Excellence are today at their annual conference in Liverpool, so now feels like a good time to look at how the agency has developed since its launch in 1999 and its plans going forward.
NICE says its Health Technology Assessment (HTA) guidances and clinical guidelines help health and social care professionals deliver the best possible care based on the best available evidence and make the best use of their money in the NHS. However, the agency’s efforts to balance clinical and cost effectiveness and the methodology used in its HTAs regularly come under fire, especially by companies who have seen their treatments turned down for use on the National Health Service. One of the reasons for this is often that whilst NICE seek expert clinical and patient opinion, it can sometimes seem as if the patient’s voice is heard as a whisper compared to the weight of academic science taken in to consideration during the process. Continue reading NICE and the Value of New Medicine→